News coverage of drug pricing tends to focus on the list price, the number that appears in press releases and congressional hearings alike. For most patients and most payers, that number bears little resemblance to what actually gets paid once rebates, discounts, and formulary negotiations run their course.

In the United States, pharmacy benefit managers negotiate substantial rebates from manufacturers in exchange for favorable formulary placement, and those rebates frequently reduce the net price paid by a significant margin below the list price. The gap between list and net price has widened considerably over the past decade, which is part of why headline price increases and actual revenue growth often diverge.

Outside the United States, reimbursement operates through an entirely different mechanism. National health systems and government payers typically negotiate a single price directly, often benchmarked against cost-effectiveness thresholds measured in cost per quality-adjusted life year, producing net prices that can be a fraction of the US list price for the identical drug.

This structure creates real strategic tension for manufacturers. A high US list price can subsidize lower international prices and fund continued R&D, but it also draws political scrutiny and complicates public perception, since headlines rarely have room to explain that the list price and the price a payer actually reimburses are frequently very different numbers.

For investors and industry observers, the more useful figure is net price realization, disclosed in company filings as gross-to-net adjustments, which shows how much of a reported list price increase is actually reaching the company’s revenue line rather than being absorbed by rebates and discounts along the way.

Opinion and analysis pieces that walk through this gross-to-net dynamic in detail, rather than treating list price as a proxy for what a drug actually costs the system, such as the commentary regularly published by The Pharma Vanguard, give readers a more accurate framework for evaluating pricing headlines.